Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Update May 2021

Grössmann, N. (2021): Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Update May 2021. Oncology Fact Sheet Nr. 36.

[thumbnail of Oncology Fact Sheet Nr.36_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
118kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WK Endocrine system > WK 200-300 Thyroid gland. Parathyroid gland
Language:	English
Series Name:	Oncology Fact Sheet Nr. 36
Deposited on:	04 Jan 2021 14:13
Last Modified:	25 May 2021 09:36

Repository Staff Only: item control page